Literature DB >> 3149239

Interference of ketanserin with baroreflex control of the circulation in the conscious spontaneously hypertensive rat.

J Smits1, F van Dorsten, H Struyker Boudier.   

Abstract

Ketanserin suppresses baroreflex-mediated tachycardia following the administration of hypotensive doses of sodium nitroprusside in conscious spontaneously hypertensive rats (SHR). The purpose of this study was to compare the baroreflex effects of ketanserin with those of the more selective S2-serotonergic receptor antagonist ritanserin and the alpha 1-blocker prazosin. In conscious SHR, both ketanserin (3 mg/kg) and prazosin (0.01 and 0.1 mg/kg) caused a significant reduction in blood pressure. Ritanserin (3 mg/kg) and the combination of a low dose of prazosin (0.01 mg/kg) and ritanserin (3 mg/kg) did not lower blood pressure significantly. Baroreflex responses were determined by measuring the maximal changes in heart period (HP = 60,000/HR) after administration of 20 to 100 micrograms/kg sodium nitroprusside. Whereas saline and prazosin lacked an effect on changes in HPmax, ketanserin reversed the decrease in delta HPmax into a significant increase. Ritanserin alone caused a slight but insignificant inhibition, whereas the combination of ritanserin and prazosin blocked the sodium nitroprusside-induced reflex tachycardia. Ritanserin, in contrast to prazosin or ketanserin, lowered resting heart rate values. We conclude that the interference of ketanserin with the baroreflex in SHR is a unique property of this agent, related to its simultaneous effects on serotonin (5-HT) S2-receptors and alpha 1-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149239     DOI: 10.2165/00003495-198800361-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  Mechanism of the hypotensive effect of ketanserin.

Authors:  J R Fozard
Journal:  J Cardiovasc Pharmacol       Date:  1982 Sep-Oct       Impact factor: 3.105

2.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

3.  Characterization of the antihypertensive properties of ketanserin (R 41 468) in rats.

Authors:  H O Kalkman; P B Timmermans; P A Van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

4.  Ketanserin and the arterial baroreceptor reflex in normotensive subjects.

Authors:  A Berdeaux; A Edouard; K Samii; J F Giudicelli
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Pharmacology of potent and selective S2-serotonergic antagonists.

Authors:  P A Janssen
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

6.  The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity.

Authors:  A G Ramage
Journal:  Eur J Pharmacol       Date:  1985-07-31       Impact factor: 4.432

7.  Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat.

Authors:  A Pettersson; K Gradin; T Hedner; B Persson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

8.  Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats.

Authors:  M L Cohen; R W Fuller; K D Kurz
Journal:  Hypertension       Date:  1983 Sep-Oct       Impact factor: 10.190

9.  LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat.

Authors:  M L Cohen; R W Fuller; K D Kurz
Journal:  J Pharmacol Exp Ther       Date:  1983-11       Impact factor: 4.030

10.  Characterization of the central sympathoinhibitory action of ketanserin.

Authors:  R B McCall; L T Harris
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.